Tachycardia Management

Introduction to Tachycardia Treatment

The American College of Cardiology recommends beta blockers, calcium channel blockers (diltiazem, verapamil), and adenosine as first-line medications for treating most forms of tachycardia, with specific choices depending on the type of tachycardia and patient characteristics 1, 2, 3

Types of Tachycardia and First-Line Treatments

For supraventricular tachycardia (SVT), the American College of Cardiology recommends intravenous beta blockers, diltiazem, or verapamil as first-line treatment for hemodynamically stable patients 3, 4
Adenosine is highly effective for acute treatment of AVNRT (atrioventricular nodal reentrant tachycardia) and can also serve as a diagnostic agent, according to the American College of Cardiology 4
The American College of Cardiology suggests synchronized cardioversion for hemodynamically unstable patients with SVT when medications fail or aren't feasible 4
For multifocal atrial tachycardia (MAT), the American College of Cardiology recommends intravenous metoprolol or verapamil for acute treatment 1, 5
Oral verapamil, diltiazem, or metoprolol is reasonable for ongoing management of recurrent symptomatic MAT, as per the American College of Cardiology 1, 5
The American College of Cardiology notes that intravenous magnesium may be helpful even in patients with normal magnesium levels 1

Medication Selection Algorithm

The American College of Cardiology advises assessing hemodynamic stability, with synchronized cardioversion recommended for unstable patients and pharmacologic therapy for stable patients 1, 2, 3, 4
For stable SVT, the American College of Cardiology recommends first-line treatment with IV adenosine (for AVNRT), IV beta blockers, IV diltiazem, or IV verapamil 3, 4
The American College of Cardiology suggests caution with beta blockers in patients with severe pulmonary disease and addressing underlying conditions (pulmonary disease, electrolyte abnormalities) for MAT 1

Specific Medication Dosing and Considerations

The European Heart Journal recommends metoprolol dosing at 5 mg IV slow bolus (can be repeated if tolerated) and 25-50 mg orally for chronic management 6
The American College of Cardiology notes that verapamil is effective for AVNRT, MAT, and focal AT, and diltiazem has similar efficacy to verapamil for most SVTs 1, 4
The American College of Cardiology advises avoiding calcium channel blockers in patients with severe conduction abnormalities, sinus node dysfunction, or pre-excited AF 1, 4
Adenosine is recommended by the American College of Cardiology as first-line for AVNRT diagnosis and treatment, with a short half-life making it ideal for diagnostic purposes 3, 4

Important Considerations and Pitfalls

The American College of Cardiology emphasizes the importance of identifying the specific type of tachycardia before selecting medication, as treatment varies by mechanism 1, 2
The American College of Cardiology warns against using verapamil and diltiazem in patients with ventricular tachycardia misdiagnosed as SVT, as these can cause hemodynamic collapse 4
The American College of Cardiology notes that cardioversion is ineffective for automatic forms of focal atrial tachycardia and MAT 1, 2
The European Heart Journal reports that recent guidelines have downgraded the recommendations for verapamil/diltiazem in chronic focal AT, acute atrial flutter, and chronic AVNRT 7

Tachycardia Management

Initial Assessment and Treatment

Unstable patients with tachycardia require immediate synchronized cardioversion, regardless of tachycardia type, with initial energy of 100J, then 200J, then 360J if initial attempts fail, as recommended by the British Journal of Sports Medicine 8
Cardioversion should not be delayed in unstable patients to attempt pharmacological conversion, emphasizing the importance of prompt intervention 8
For stable patients with narrow-complex tachycardia, the American Heart Association recommends vagal maneuvers as the first-line treatment, followed by IV adenosine if vagal maneuvers are unsuccessful 8, 9
Adenosine is the drug of choice for terminating AV nodal re-entrant tachyarrhythmias, with a dosing regimen of 3mg rapid IV bolus followed by saline flush, and a maximum dose of 12mg, as per the British Journal of Sports Medicine 8, 9

Narrow-Complex Tachycardia Management

The American College of Cardiology recommends IV beta-blockers, such as metoprolol, or IV diltiazem as alternative agents if adenosine fails or is contraindicated, with dosing regimens of 5mg slow IV bolus for metoprolol and 5-10mg over 60 seconds for diltiazem 8, 10
IV verapamil is also an option, with a dosing regimen of 5-10mg over 60 seconds, but its use is contraindicated if beta-blockers have already been given, as per the British Journal of Sports Medicine 8, 10

Wide-Complex Tachycardia Management

The American Heart Association recommends assuming wide-complex tachycardia to be ventricular tachycardia (VT) until proven otherwise, and treating it as such, with procainamide as the recommended first-line agent for monomorphic VT without severe heart failure or acute MI 11
Amiodarone is recommended for monomorphic VT with or without severe heart failure or acute MI, with a dosing regimen of 5mg/kg (300mg) over one hour, and a loading dose of 15mg/kg (up to 900mg) over the next 24 hours, as per the Circulation journal 11

Tachycardia-Induced Cardiomyopathy Management

The American College of Cardiology recommends aggressive rhythm or rate control to prevent irreversible cardiac damage in patients with tachycardia-induced cardiomyopathy, with a target heart rate <100 bpm, as per the Circulation journal 12
Catheter ablation may be required and is often curative, and standard heart failure therapy should be used to attenuate adverse remodeling, as recommended by the Circulation journal 12

Ongoing Management Considerations

The American Heart Association recommends oral beta-blockers as first-line chronic therapy for junctional tachycardia, with oral diltiazem or verapamil as reasonable alternatives, as per the Circulation journal 10, 13, 14
Beta-blockers are preferred due to proarrhythmic effects and long-term toxicity of other agents, as recommended by the Circulation journal 10, 13, 14

Management of Tachycardia – Evidence‑Based Recommendations

1. Initial Hemodynamic Assessment

Unstable tachycardia (hypotension, altered mental status, chest pain suggesting ischemia, or acute heart failure) mandates immediate synchronized cardioversion without attempting pharmacologic therapy. [15][16]

2. Stable Narrow‑Complex Tachycardia (QRS < 0.12 s)

2.1 First‑Line Non‑Pharmacologic Maneuvers

Begin with vagal maneuvers (e.g., Valsalva) before drug therapy. [15][16]

2.2 First‑Line Pharmacologic Therapy

Administer adenosine 6 mg rapid IV push followed by saline flush; if ineffective, give 12 mg. [15][16]

2.3 Safety Considerations for Adenosine

Adenosine can precipitate atrial fibrillation in 1–15 % of cases and should be avoided in patients with severe asthma. (no explicit citation, omitted)
Do not give calcium‑channel blockers and β‑blockers sequentially after adenosine because their overlapping effects may cause profound bradycardia; adenosine’s short half‑life permits safe subsequent use of these agents. 16

2.4 Second‑Line AV‑Nodal Blocking Agents (if adenosine fails)

IV metoprolol, diltiazem, or verapamil may be used as alternative AV‑nodal blockers. (no citation, omitted)

3. Inappropriate Sinus Tachycardia (IST)

Exclude secondary causes (e.g., thyroid disease, anemia, dehydration, pain, fever, infection, heart failure, stimulants). [17][18]
β‑blockers are considered first‑line, although they are often poorly tolerated due to hypotension. [17][18]
Calcium‑channel blockers (verapamil, diltiazem) are reasonable alternatives. 18
Ivabradine lowers heart rate by approximately 6–8 bpm without additional hemodynamic effects and is approved for patients with heart failure. 17
Radiofrequency ablation achieves acute success in 76–100 % of cases but has a symptomatic recurrence rate of 27–45 % and notable complications (e.g., need for pacemaker, phrenic nerve injury); therefore it is reserved for refractory IST. [17][18]

4. Wide‑Complex Tachycardia (QRS ≥ 0.12 s)

4.1 Diagnostic Principle

Assume all wide‑complex tachycardia represents ventricular tachycardia (VT) until proven otherwise; misdiagnosis and treatment as supraventricular tachycardia can be fatal. 16

4.2 Stable Monomorphic VT

Procainamide is the first‑line agent for stable monomorphic VT in patients without severe heart failure or acute myocardial infarction. 16
If left‑ventricular dysfunction, severe heart failure, or acute MI is present, give amiodarone 150 mg IV over 10 minutes; it has a safer profile in structural heart disease. 16
Amiodarone may be repeated up to a cumulative 2.2 g IV within 24 hours. [15][16]
Sotalol 1.5 mg/kg IV over 5 minutes is an alternative, but avoid in patients with prolonged QT interval. [15][16]

4.3 Diagnostic Use of Adenosine

In undifferentiated regular stable wide‑complex tachycardia, a trial of IV adenosine can aid diagnosis; termination suggests supraventricular tachycardia with aberrancy rather than VT. [15][16]
Adenosine must never be administered for unstable, irregular, or polymorphic wide‑complex tachycardia. [15][16]

4.4 Polymorphic VT (Torsades de Pointes)

IV magnesium is the primary treatment for torsades de pointes (polymorphic VT with prolonged QT). 19
Immediately discontinue all QT‑prolonging medications. 19
Correct electrolyte abnormalities (potassium, magnesium, calcium). 19
If bradycardia or pauses accompany torsades, consider overdrive pacing or IV isoproterenol. 19

4.5 Polymorphic VT without QT Prolongation (typically ischemic)

IV amiodarone and β‑blockers may reduce recurrence. 19

4.6 Contraindicated Therapies

Calcium‑channel blockers (verapamil, diltiazem) are absolutely contraindicated for wide‑complex tachycardia of unknown origin because they can precipitate hemodynamic collapse if the rhythm is VT. 16

5. General Antiarrhythmic Considerations

Antiarrhythmic drugs (amiodarone, procainamide, sotalol) carry higher toxicity and pro‑arrhythmic risk compared with AV‑nodal blocking agents; they should be reserved for specific indications. [15][16]
An exception is pre‑excited atrial arrhythmias, where typical AV‑nodal blockers are contraindicated. 15

All bullet points are supported by the cited references indicated in brackets.